



(51) International Patent Classification:

A61M 31/00 (2006.01) C07D 211/96 (2006.01)
C07D 207/48 (2006.01)

(21) International Application Number:

PCT/US2021/072510

(22) International Filing Date:

19 November 2021 (19.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/116,042 19 November 2020 (19.11.2020) US

(71) Applicant: **PLIANT THERAPEUTICS, INC.** [US/US];
260 Littlefield Avenue, South San Francisco, California
94080 (US).

(72) Inventors: **CHA, Jacob**; c/o Pliant Therapeutics, Inc., 260
Littlefield Avenue, South San Francisco, California 94080
(US). **LEFTHERIS, Katerina**; c/o Pliant Therapeutics,
Inc., 260 Littlefield Avenue, South San Francisco, Califor-
nia 94080 (US). **QI, Gao**; c/o J-Star Research Inc., 6 Cedar-

brook Drive, Cranbury Township, New Jersey 08512 (US).
WANG, Jian; c/o J-Star Research Inc., 6 Cedarbrook Drive,
Cranbury Township, New Jersey 08512 (US). **ZHAO, Dalian**;
c/o J-Star Research Inc., 6 Cedarbrook Drive, Cran-
bury Township, New Jersey 08512 (US).


(74) Agent: **REANEY, Shannon** et al.; Morrison & Foerster
LLP, 755 Page Mill Road, Palo Alto, California 94304-1018
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: INTEGRIN INHIBITOR AND USES THEREOF

FIG. 1A



(57) Abstract: Provided herein are integrin inhibitors, compositions thereof, and methods of their uses. Crystalline forms of salts of the inhibitors are also described, along with methods of preparing the crystalline forms. X-ray powder diffraction data, thermogravimetric analysis, and differential scanning calorimetry data are provided for the crystalline forms. The integrin inhibitors are useful for treatment of, inter alia, fibrotic diseases.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*